Literature DB >> 18030553

[Invasive candidiasis in the critically ill, patient non-neutropenic].

Ines Schwetz1, Wolfgang Domej, Robert Krause.   

Abstract

Invasive candidiasis can occur in immunosuppressed patients as well as in critically ill, non-immunocompromised patients and is associated with high mortality (20-40 %). Intestinal Candida colonisation is an important source for invasive candidiasis. Risk factors for the development of invasive candidiasis include presence of an intravascular device, organ dysfunction, impaired mucosal or skin barrier function, therapy with antacids or corticosteroids, prolonged stay at the ICU, total parenteral nutrition and prolonged antibiotic therapy. Among patients with invasive candidiasis, antifungal treatment should be started without delay. Antifungal prophylaxis is currently not recommended in critically ill, non-immunocompromised patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18030553     DOI: 10.1007/s10354-007-0464-0

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  21 in total

1.  Role of Candida in antibiotic-associated diarrhea.

Authors:  R Krause; E Schwab; D Bachhiesl; F Daxböck; C Wenisch; G J Krejs; E C Reisinger
Journal:  J Infect Dis       Date:  2001-08-31       Impact factor: 5.226

Review 2.  Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.

Authors:  Philippe Eggimann; Jorge Garbino; Didier Pittet
Journal:  Lancet Infect Dis       Date:  2003-11       Impact factor: 25.071

3.  Hospital-acquired candidemia. The attributable mortality and excess length of stay.

Authors:  S B Wey; M Mori; M A Pfaller; R F Woolson; R P Wenzel
Journal:  Arch Intern Med       Date:  1988-12

Review 4.  Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis.

Authors:  Mario Cruciani; Fausto de Lalla; Carlo Mengoli
Journal:  Intensive Care Med       Date:  2005-09-20       Impact factor: 17.440

5.  Oral nystatin prophylaxis of Candida spp. colonization in ventilated critically ill patients.

Authors:  Sandrine Normand; Bruno François; Marie-Laure Dardé; Bernard Bouteille; Michel Bonnivard; Pierre-Marie Preux; Hervé Gastinne; Philippe Vignon
Journal:  Intensive Care Med       Date:  2005-09-30       Impact factor: 17.440

6.  Predominant pathogens in hospital infections.

Authors:  W R Jarvis; W J Martone
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

7.  A comparison of phospholipase activity, cellular adherence and pathogenicity of yeasts.

Authors:  K Barrett-Bee; Y Hayes; R G Wilson; J F Ryley
Journal:  J Gen Microbiol       Date:  1985-05

Review 8.  Epidemiology of nosocomial fungal infections, with emphasis on Candida species.

Authors:  W R Jarvis
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

9.  Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination.

Authors:  Jorge Garbino; Daniel P Lew; Jacques-A Romand; Stéphane Hugonnet; Raymond Auckenthaler; Didier Pittet
Journal:  Intensive Care Med       Date:  2002-11-01       Impact factor: 17.440

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.